VCPKMT

Across TCGA pan-cancer cohorts, VCPKMT mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated VCPKMT data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher VCPKMT mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated VCPKMT expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where VCPKMT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.345	0.770	.001	55	view →
LSCC	OS	Median	All	0.937	0.723	<.001	12	view →
HNSC	DFS	Median	IV	0.695	0.918	.038	3	view →
PDAC	OS	Median	II,III,IV	0.857	0.440	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

VCPKMT–LUAD (DFS)

Open the LUAD breakdown →